<DOC>
	<DOCNO>NCT02626884</DOCNO>
	<brief_summary>The purpose trial determine 1 . Disease stabilization/response rate six 21-day cycle ibrutinib 2 . Remission status six , twelve 20 21-day cycle ibrutinib</brief_summary>
	<brief_title>Ibrutinib Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma ( NLPHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion Criteria ( key criterion ) : 1 . Histologically proven relapse nodular lymphocytepredominant Hodgkin lymphoma ( NLPHL ) confirm expert review 2 . Age entry 1899 year 3 . ECOG status 02 4 . Absolute leukocyte count &gt; 2.500/mm3 5 . Absolute neutrophil count &gt; 1.000/mm3 independent growth factor support 6 . Platelet count &gt; 100.000/mm3 &gt; 50.000/mm3 case bone marrow involvement independent transfusion support either situation 7 . GPT GOT â‰¤ 3 x upper limit normal ( ULN ) Exclusion Criteria ( key criterion ) : 1 . Classical HL ( cHL ) composite lymphoma 2 . Known central nervous lymphoma 3 . Prior Btk inhibitor treatment 4 . Life expectancy &lt; 3 month 5 . Major surgery within 4 week study inclusion 6 . History stroke intracranial hemorrhage within 6 month prior first study drug 7 . Current anticoagulation warfarin equivalent vitamin K antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>